Olmesartan ophthalmic

Drug Profile

Olmesartan ophthalmic

Alternative Names: CS 088; DE 092; Ophthalmic olmesartan - Santen

Latest Information Update: 25 Mar 2009

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Santen Pharmaceutical
  • Class Antihypertensives; Eye disorder therapies; Imidazoles; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Glaucoma; Ocular hypertension

Most Recent Events

  • 05 Nov 2008 Discontinued - Phase-II for Glaucoma in European Union (Ophthalmic)
  • 05 Nov 2008 Discontinued - Phase-II for Glaucoma in Japan (Ophthalmic)
  • 05 Nov 2008 Discontinued - Phase-II for Glaucoma in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top